Okabena Investment Services Inc. Buys Shares of 9,403 Globus Medical, Inc. $GMED

Okabena Investment Services Inc. bought a new stake in Globus Medical, Inc. (NYSE:GMED) in the fourth quarter, HoldingsChannel reports. The fund bought 9,403 shares of the medical device company’s stock, valued at approximately $821,000.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in GMED. AQR Capital Management LLC grew its stake in Globus Medical by 45.9% in the first quarter. AQR Capital Management LLC now owns 22,510 shares of the medical device company’s stock valued at $1,622,000 after acquiring an additional 7,086 shares during the period. Integrated Wealth Concepts LLC boosted its position in shares of Globus Medical by 33.0% during the first quarter. Integrated Wealth Concepts LLC now owns 4,375 shares of the medical device company’s stock worth $320,000 after buying an additional 1,085 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of Globus Medical by 38.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 30,649 shares of the medical device company’s stock worth $2,228,000 after buying an additional 8,540 shares during the period. Jones Financial Companies Lllp boosted its position in shares of Globus Medical by 237.3% during the first quarter. Jones Financial Companies Lllp now owns 850 shares of the medical device company’s stock worth $62,000 after buying an additional 598 shares during the period. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in shares of Globus Medical by 8.8% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 347,527 shares of the medical device company’s stock worth $25,439,000 after buying an additional 28,027 shares during the period. 95.16% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Globus Medical

In related news, Director David D. Davidar sold 25,000 shares of the company’s stock in a transaction dated Friday, June 5th. The stock was sold at an average price of $80.76, for a total transaction of $2,019,000.00. Following the sale, the director owned 510,175 shares in the company, valued at approximately $41,201,733. This represents a 4.67% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 18.38% of the company’s stock.

Analyst Ratings Changes

Several research analysts have recently weighed in on the company. Piper Sandler reduced their price objective on Globus Medical from $115.00 to $100.00 and set an “overweight” rating for the company in a research report on Monday. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Globus Medical in a research report on Wednesday, April 15th. Wells Fargo & Company reduced their price objective on Globus Medical from $104.00 to $103.00 and set an “overweight” rating for the company in a research report on Friday, May 8th. Barclays upped their price objective on Globus Medical from $118.00 to $123.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 25th. Finally, Royal Bank Of Canada upped their price objective on Globus Medical from $115.00 to $120.00 and gave the stock an “outperform” rating in a research report on Friday, May 8th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $105.00.

Globus Medical Stock Performance

GMED opened at $77.25 on Tuesday. Globus Medical, Inc. has a 52-week low of $51.79 and a 52-week high of $101.40. The firm has a market capitalization of $10.49 billion, a PE ratio of 17.97, a PEG ratio of 1.66 and a beta of 0.95. The business’s 50-day simple moving average is $85.56 and its 200 day simple moving average is $88.00.

Globus Medical (NYSE:GMED) last released its earnings results on Thursday, May 7th. The medical device company reported $1.12 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.92 by $0.20. Globus Medical had a return on equity of 13.46% and a net margin of 18.92%.The business had revenue of $759.85 million for the quarter, compared to analyst estimates of $740.35 million. During the same quarter in the prior year, the company posted $0.68 earnings per share. Globus Medical’s revenue was up 27.0% on a year-over-year basis. Globus Medical has set its FY 2026 guidance at 4.700-4.800 EPS. On average, research analysts forecast that Globus Medical, Inc. will post 4.74 earnings per share for the current year.

Globus Medical Profile

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.